GlassScriptPhysician profile
Kelley A Bennett
NPI 1932267903
$4,665.54
in general payments reported to CMS, 2019-2025
32 companies · $1,301 in 2025
The $1,301 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $319 · 2022: $754 · 2023: $1,010 · 2024: $1,282 · 2025: $1,301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,593.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,593.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $467.02 | 2024 | Airsupra |
| Janssen Pharmaceuticals, INC | $354.31 | 2023-2025 | Spravato |
| Neurocrine Biosciences, INC. | $266.09 | 2023-2025 | Ingrezza |
| Dexcom, INC. | $257.36 | 2023-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Sanofi-Aventis U.S. LLC | $231.62 | 2023-2025 | |
| Abbvie INC. | $226.78 | 2024 | |
| Alexion Pharmaceuticals, INC. | $215.72 | 2022-2025 | |
| Myriad Genetic Laboratories, INC. | $182.79 | 2022 | |
| Boston Scientific Corporation | $148.51 | 2022 | |
| Lilly USA, LLC | $140.59 | 2022-2024 | Mounjaro |
| Corcept Therapeutics | $125.00 | 2021 | |
| Genzyme Corporation | $123.23 | 2023 | |
| Kyowa Kirin, INC. | $121.84 | 2025 | |
| Axsome Therapeutics, INC. | $121.84 | 2024 | Sunosi |
| Amgen INC. | $121.84 | 2025 | Krystexxa |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $115.81 | 2023 | |
| Phathom Pharmaceuticals, INC. | $112.93 | 2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.61 | 2021 | |
| Abbott Laboratories | $107.52 | 2024 | Freestyle Libre 3 |
| Aimmune Therapeutics, INC. | $103.32 | 2024 | |
| Kci USA, INC. | $98.08 | 2023 | Activ.A.C., 3m Cavilon, V.A.C. Dermatac |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $97.48 | 2025 | |
| Ars Pharmaceuticals Operations, INC. | $97.32 | 2025 | Neffy |
| Daiichi Sankyo INC. | $96.02 | 2024 | Enhertu |
| Ironshore Pharmaceuticals INC. | $94.02 | 2023 | Jornay Pm |
| Zealand Pharma US, INC. | $86.27 | 2022 | |
| Idorsia Pharmaceuticals US INC | $85.40 | 2023 | Quviviq |
| Glaxosmithkline, LLC. | $84.93 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $81.87 | 2022 | |
| Novo Nordisk INC | $79.69 | 2022 | |
| Sumitomo Pharma America, INC. | $71.49 | 2024 | Myfembree |
| Pfizer INC. | $40.24 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelley Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.